View Older Stories View More Recent Stories

Jul 2, 2019 11:03AM Seelos Therapeutics (SEEL) Receives USPTO Notice of Allowance for SLS-005 in New Indication
Jul 2, 2019 11:00AM Seelos Therapeutics Receives Notice of Allowance for a US Patent for SLS-005 in New Indication of Friedreich Ataxia
Jul 2, 2019 11:00AM Seelos Therapeutics Receives Notice of Allowance for a US Patent for SLS-005 in New Indication of Friedreich Ataxia
Jul 1, 2019 09:00AM Seelos Therapeutics Added to Russell Microcap® Index
Jul 1, 2019 09:00AM Seelos Therapeutics Added to Russell Microcap® Index
Jun 27, 2019 07:19AM Seelos Therapeutics (SEEL) Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address PD from Duke University
Jun 27, 2019 07:00AM Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University
Jun 27, 2019 07:00AM Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University
Jun 6, 2019 07:00AM Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
Jun 6, 2019 07:00AM Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
May 21, 2019 08:30AM Seelos Therapeutics Reports Q1 2019 Pipeline Update
May 21, 2019 08:30AM Seelos Therapeutics Reports Q1 2019 Pipeline Update
Apr 16, 2019 08:00AM Seelos Therapeutics to Participate at the Jefferies 2019 Global Healthcare Conference in NYC
Apr 16, 2019 08:00AM Seelos Therapeutics to Participate at the Jefferies 2019 Global Healthcare Conference in NYC
Jan 25, 2019 09:00AM Ligand Partner Seelos Therapeutics Becomes a Public Company
View More Recent Stories View Older Stories